miR-210 promoted cisplatin drug sensitivity in colorectal cancer through Wnt/β-catenin pathway
Objective To investigate the effect and mechanism of miR-210 on the proliferation and cisplatin(DDP)sensitivity of colorectal cancer cells.Methods The expression of miR-210 in human normal colonic epi-thelial cells(HCoEpiC),colorectal cancer cells(HCT-116,HT-29,SW620)and cisplatin resistant cell lines(HCT-116/DDP)were detected by RT-qPCR.Proliferation and apoptosis of HCT-116 cells after miR-210 over-expression or interference were detected by CCK-8 and Annexin V-FITC/PI assay,respectively.HCT-116/DDP cells were randomly divided into Control group,miR-210 mimics group and miR-210 inhibitor group.After DDP(80 μmol/L)or Control treatment for 24 h,the cell activity of HCT-116/DDP cells was detected by CCK-8.Apoptosis was detected by Annexin V-FITC/PI double staining,and expression of apoptosis-related proteins(Bad,Bcl-2,Cleaved caspase-3),drug-resistance related proteins(ABCG2,MRP2,P-gp)and Wnt/β-cate-nin pathway proteins were detected by Western blot assay.Results Compared with HCoEpiC cells,the expres-sion of miR-210 in colorectal cancer cells(HCT-116,HT-29,SW620)was significantly decreased,and the ex-pression of miR-210 in HCT-116/DDP cells was further decreased than that in HCT-116 cells.miR-210 mimics significantly inhibited the cell viability and promote apoptosis of colorectal cancer cells and cisplatin resistant strains.miR-210 inhibitor had the opposite effect.In HCT-116/DDP cells,compared with the DDP group,the DDP+mimics group could significantly inhibit cell activity,promote cell apoptosis,promote the expression of Bad and Cleaved caspase-3,inhibit expression of Bcl-2,inhibit expression of drug-resistant related proteins(P-gp,MRP2,ABCG2),and inhibit the expression of Wnt3a and β-catenin.With miR-210 inhibitor,the opposite effect was found.Conclusion miR-210 may affect the expression of drug-resistant related proteins(P-gp,AB-CG2,MRP2)by regulating Wnt/β-catenin pathway,and finally promote the drug sensitivity of HCT-116/DDP resistant cells to cisplatin.